MiR‐22, a serum predictor of poor outcome and therapy response in diffuse large B‐cell lymphoma patients
Federica Rinaldi, Francesco Marchesi, Francesca Palombi, Andrea Pelosi, Anna Laura Di Pace, Andrea Sacconi, Irene Terrenato, Ombretta Annibali, Valeria Tomarchio, Mirella Marino, Maria Cantonetti, Sara Vaccarini, Elena Papa, Lorenzo Moretta, Francesco Bertoni, Andrea Mengarelli, Giulia Regazzo, Maria Giulia Rizzo
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, heterogeneous neoplasm where prognostication and therapeutic decision are challenging. The available prognostic tools are not able to identify all patients refractory to treatment. MicroRNAs, small RNAs frequently deregulated in cancer, stably circulate in biofluids, representing interesting candidates for non-invasive biomarkers. Here we validated serum miR-22, an evolutionarily conserved microRNA, as a prognostic/predictive biomarker in DLBCL. Moreover, we found that its expression and release from DLBCL cells are related to therapy response and adversely affect cell proliferation. These results suggest that miR-22 is a promising complementary or even independent non-invasive biomarker for DLBCL management.